Even though TMPRSS2‐ETS gene fusion is not a tumor progression marker but due to its relevance with aggressiveness, TMPRSS2‐ETS gene fusion remains a curious novel target for therapeutic development in PCa. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.